Goldman Sachs to invest $150 million in Biocon's IPO-bound subsidiary Biocon Biologics
As per the terms of the proposed agreement, Goldman Sachs will be issued Optionally Convertible Debentures at a post money equity valuation of $3.94 billion. The transaction is subject to customary approvals and conditions